Abstract
The integrin family of cell surface receptors were principally thought to be involved in cell adhesion. Intense study has shown that these glycoproteins also regulate a diverse range of physiological processes. Inappropriate activation of integrins has been implicated in many pathological processes. Recent studies have shown that these molecules play a key role in the early stages of liver metastasis in colorectal cancer. In vivo experiments have demonstrated that integrins are involved in tumour cell targeting, arrest, adhesion and migration within the hepatic microcirculation. Indeed functional blocking of specific integrins has been shown to significantly impair these early stages of metastasis development. This review examines the current knowledge of integrin participation in this area and highlights the future therapeutic implications. Future targeted therapy against specific integrins would allow not only functional blocking but would provide the potential to deliver specific anti-cancer therapy.
Keywords: Colorectal cancer, liver metastasis, integrin, treatment
Current Pharmaceutical Design
Title: Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Volume: 14 Issue: 3
Author(s): Alexander M. Seifalian, John H. Robertson, Arthur M. Iga, Kevin M. Sales and Marc C. Winslet
Affiliation:
Keywords: Colorectal cancer, liver metastasis, integrin, treatment
Abstract: The integrin family of cell surface receptors were principally thought to be involved in cell adhesion. Intense study has shown that these glycoproteins also regulate a diverse range of physiological processes. Inappropriate activation of integrins has been implicated in many pathological processes. Recent studies have shown that these molecules play a key role in the early stages of liver metastasis in colorectal cancer. In vivo experiments have demonstrated that integrins are involved in tumour cell targeting, arrest, adhesion and migration within the hepatic microcirculation. Indeed functional blocking of specific integrins has been shown to significantly impair these early stages of metastasis development. This review examines the current knowledge of integrin participation in this area and highlights the future therapeutic implications. Future targeted therapy against specific integrins would allow not only functional blocking but would provide the potential to deliver specific anti-cancer therapy.
Export Options
About this article
Cite this article as:
Seifalian M. Alexander, Robertson H. John, Iga M. Arthur, Sales M. Kevin and Winslet C. Marc, Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases, Current Pharmaceutical Design 2008; 14 (3) . https://dx.doi.org/10.2174/138161208783413284
DOI https://dx.doi.org/10.2174/138161208783413284 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Characterization and in vitro Cytotoxicity Evaluation of Meloxicam Loaded PEGylated Mixed Micelles Fabricated Using Quality by Design Approach
Drug Delivery Letters Studying the Gut Microbiome of Latin America and Hispanic/Latino Populations. Insight into Obesity and Diabetes: Systematic Review
Current Diabetes Reviews Rational Drug Design for Identifying Novel Multi-target Inhibitors for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum
Current Topics in Medicinal Chemistry Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology The Role of Genetic Polymorphisms in Metabolism of Carcinogenic Heterocyclic Aromatic Amines
Current Drug Metabolism Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery Activation of the dsRNA-Activated Protein Kinase PKR in Mitochondrial Dysfunction and Inflammatory Stress in Metabolic Syndrome
Current Pharmaceutical Design Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy The p53 Pathway Encounters the MicroRNA World
Current Genomics